초록 ▼

A method of increasing a prostate specific antigen (PSA) doubling time in treating a patient. A subject with rising serum PSA is selected. A composition is administered to the subject comprising a therapeutically effective amount of a pomegranate extract comprising a higher content of high molecular

A method of increasing a prostate specific antigen (PSA) doubling time in treating a patient. A subject with rising serum PSA is selected. A composition is administered to the subject comprising a therapeutically effective amount of a pomegranate extract comprising a higher content of high molecular weight polyphenol compared to pomegranate juice from arils. The therapeutically effective amount increases a prostate specific antigen doubling time. The pomegranate extract is formed from an insoluble byproduct component obtained by placing pomegranate solids in an aqueous solution, heating the aqueous solution to between about 60° F. to about 210° F., adding at least one enzyme to the aqueous solution, and removing residual insoluble solid materials from the aqueous solution.

대표청구항 ▼

1. A method for increasing a prostate specific antigen (PSA) doubling time in a patient with prostate cancer comprising: selecting a patient with rising serum PSA; andadministering a daily dosage of a pomegranate extract to said patient with rising serum PSA, wherein said daily dosage comprises abou

1. A method for increasing a prostate specific antigen (PSA) doubling time in a patient with prostate cancer comprising: selecting a patient with rising serum PSA; andadministering a daily dosage of a pomegranate extract to said patient with rising serum PSA, wherein said daily dosage comprises about 30 μmols to about 3000 μmols of polyphenols, wherein said pomegranate extract is produced by a process comprising:crushing and squeezing pomegranate solids suspended in an aqueous solution;heating said aqueous solution to between about 60° F. to about 210° F.;adding at least one enzyme to said aqueous solution; andprocessing said aqueous solution to separate a supernatant from residual insoluble solid materials, wherein said pomegranate extract comprises said supernatant. 2. The method of claim 1, wherein said aqueous solution is heated to between about 85° F. to about 185° F. 3. The method of claim 1, wherein said aqueous solution is heated to between about 100° F. to about 160° F. 4. The method of claim 1, wherein said pomegranate extract is administered daily over an extended period to modulate serum PSA levels. 5. The method of claim 4, wherein said daily dosage comprises about 30 μmol to 3000 μmol of polyphenols. 6. The method of claim 4, wherein said extended period is at least three months. 7. The method of claim 4, wherein said extended period is at least one year. 8. The method of claim 4, wherein said extended period is at least two years. 9. The method of claim 4, wherein said pomegranate extract further comprises a pharmaceutically acceptable carrier. 10. The method of claim 4, wherein said daily dosage is in a form selected from tablets, suspensions, implants, solutions, emulsions, capsules, powders, syrups, liquid compositions, ointments, lotions, creams, pastes, and gels. 11. The method of claim 1, wherein said pomegranate extract is in a form selected from nutritional supplements, pharmaceutical preparations, vitamin supplements, food additives, or foods supplements. 12. The method of claim 1, wherein said pomegranate extract comprises a solid extract. 13. The method of claim 1, wherein said pomegranate extract comprises a liquid extract. 14. A method for modulating the growth and progression of cancerous cells comprising: selecting a patient cancerous cell growth; andadministering a daily dosage of a pomegranate extract, wherein said daily dosage comprises about 30 μmols to about 3000 μmols of polyphenols, wherein said pomegranate extract is formed by:crushing and squeezing pomegranate solids suspended in an aqueous solution;heating said aqueous solution to between about 60° F. to about 210° F.;adding at least one enzyme to said aqueous solution; andprocessing said aqueous solution to separate a supernatant from residual insoluble solid materials, wherein said pomegranate extract comprises said supernatant. 15. The method of claim 14, wherein said aqueous solution is heated to between about 85° F. to about 185° F. 16. The method of claim 14, wherein said aqueous solution is heated to between about 100° F. to about 160° F. 17. The method of claim 14, wherein said pomegranate extract is administered daily over an extended period to modulate the growth of cancerous cells. 18. The method of claim 17, wherein said daily dosage is in a form selected from tablets, suspensions, implants, solutions, emulsions, capsules, powders, syrups, liquid compositions, ointments, lotions, creams, pastes, and gels.